Premium
Immune Checkpoint PD‐1/PD‐L1: Is There Life Beyond Antibodies?
Author(s) -
Konstantinidou Markella,
ZarganesTzitzikas Tryfon,
MagieraMularz Katarzyna,
Holak Tad A.,
Dömling Alexander
Publication year - 2018
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201710407
Subject(s) - monoclonal antibody , cocrystal , pd l1 , immunotherapy , pembrolizumab , antibody , palladium , immune checkpoint , immune system , monoclonal , nivolumab , cancer immunotherapy , cancer research , medicine , chemistry , immunology , molecule , biochemistry , catalysis , hydrogen bond , organic chemistry
The PD‐1/PD‐L1 interaction has emerged as a significant target in cancer immunotherapy. Current medications include monoclonal antibodies, which have shown impressive clinical results in the treatment of several types of tumors. The cocrystal structure of human PD‐1 and PD‐L1 is expected to be a valuable starting point for the design of novel inhibitors, along with the recent crystal structures with monoclonal antibodies, small molecules, and macrocycles.